Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment.

Front Immunol · 2021 · PMC8339919 · PMID 34367149

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Administration of dinutuximab beta resulted in a highly significant and temporally cohesive induction of the proinflammatory cytokines measured on day 1 prior to start of ch14.18/CHO infusion and on day 5 of any treatment cycle ( Figure 2 ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.